The Effects of Exosomes in Otitis Media With Effusion

The Effects of Exosomes in Children With Adenoid Hypertrophy Accompanied by Otitis Media With Effusion

The particularity of adenoids, as a reservoir of bacterial pathogens and immune molecules, is known to be significantly involved in children with otitis media with effusion (OME). As an important carrier of intercellular substance transfer and signal transduction, exosomes with different biological functions can be secreted by different types of cells. There remains significant uncertainty regarding the clinical transmitter of exosomes to OME, especially in its pathophysiologic development. In this study, the investigators try to elucidate the biological functions of exosomes in children with adenoid hypertrophy accompanied by OME.

Patients with adenoid hypertrophy or otitis media will be separated into three groups: those with adenoid hypertrophy, with otitis media and with adenoid hypertrophy and otitis media both, as well as a healthy control group. Participants in the four groups will have their middle ear effusion, nasopharyngeal secretion, and peripheral blood samples taken, from which exosomes will be separated for further analysis. Adenoidectomy will be conducted in adenoid hypertrophy accompanied by OME and adenoid hypertrophy alone and their adenoid tissue will be collected. Blood will be collected again 3 months after surgery and middle ear and nasopharyngeal examinations will be performed. Exosomes will be isolated for follow-up studies as before surgery. Investigators will also use proteome research, exosome biomarkers, and high-throughput sequencing to examine the pathophysiology of OME, particularly inflammation-related etiology, in order to provide novel ideas for OME diagnosis and treatment.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

This study will explore the pathogenesis of OME by detecting the exosome in middle ear fluid, nasopharyngeal secretions and peripheral blood in order to identify areas of opportunity for future research and to provide a theoretical basis for drug development for the treatment of secretory otitis media.

240 subjects will be recruited from Eye and ENT hospital of Fudan University or the community. They will be divided into four groups: adenoid hypertrophy accompanied by OME (group OA, n=60), adenoid hypertrophy alone (group CA, n=60), OME alone (group CO, n=60) and healthy control group (children without OME or adenoid hypertrophy, n=60). All participants will undergo the examinations of middle ear and nasopharynx in addition to blood collection when they get into the groups. The exosomes will be isolated form middle ear effusions, nasopharyngeal secretions/adenoid tissue, and peripheral blood collected from all participants. The OA and CA groups will undergo adenoidectomy and their adenoid tissue will be collected. Blood will be collected again 3 months after surgery and middle ear and nasopharyngeal examinations will be performed. Exosomes will be isolated for follow-up studies as before surgery.

The primary outcome measures will be (1) ANOVA of the alterations and related gene expression of exosome contents in nasopharyngeal secretions in the four groups; (2) microbial alterations and the exosomes from biofilm on the surface of the adenoids in OA and CA groups preoperative and postoperative; and (3) the differences of exosomes from peripheral blood samples in OA and CA groups preoperative and postoperative.

Study Type

Observational

Enrollment (Anticipated)

240

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years to 8 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

240 subjects will be recruited from Eye and ENT hospital of Fudan University or the community.

Description

Inclusion Criteria:

OME-Adenoid (OA) group:

  1. Children aged between 4 and 10 years old.
  2. Diagnosis of chronic otitis media with effusion, and the course of disease is at least 3 months.
  3. There are varying degrees of hearing loss. PTA (The mean hearing threshold of 500Hz, 1000Hz and 2000Hz) ≥ 30dB.
  4. Nasopharyngeal lateral X-ray showing A/N > 0.6 of adenoids.

Control-Adenoid (CA) group:

  1. Children aged between 4 and 10 years old.
  2. Nasopharyngeal lateral X-ray showing A/N > 0.6 of adenoids.

Control-OME (CO) group:

  1. Children aged between 4 and 10 years old.
  2. Diagnosis of chronic otitis media with effusion, and the course of disease is at least 3 months.
  3. There are varying degrees of hearing loss. PTA (The mean hearing threshold of 500Hz, 1000Hz and 2000Hz) ≥ 30dB.

Exclusion Criteria:

  1. Patients who have had one or more episodes of otitis media in the previous one year.
  2. Any immunologic diseases.
  3. Any intrinsic diseases of hearing system, anatomic or physiologic defect of the ear.
  4. Pharmacologic abnormality.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
OA: OME-Adenoid group
Patients who meet the follow inclusion criteria will be considered eligible as the OME-Adenoid (OA) group
Adenoidectomy will be conducted in OA and CA groups
CA: Control-Adenoid group
Patients who meet the follow inclusion criteria will be considered eligible as the Control-Adenoid (CA) group
Adenoidectomy will be conducted in OA and CA groups
CO: Control-OME group
Patients who meet the follow inclusion criteria will be considered eligible as the Control-OME (CO) group
control group
Patients without OME and adenoid hypertrophy will be considered eligible as the control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
differential gene expression
Time Frame: 3 months
ANOVA of the alterations and related gene expression of exosome contents in nasopharyngeal secretions in the four groups
3 months
detection of adenoids
Time Frame: 3 months
microbial alterations and the exosomes from biofilm on the surface of the adenoids in OA and CA groups preoperative and postoperative
3 months
detection of exosomes
Time Frame: 3 months
the differences of exosomes from peripheral blood samples in OA and CA groups preoperative and postoperative
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

September 1, 2022

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

May 1, 2024

Study Registration Dates

First Submitted

May 30, 2022

First Submitted That Met QC Criteria

May 30, 2022

First Posted (Actual)

June 2, 2022

Study Record Updates

Last Update Posted (Actual)

June 2, 2022

Last Update Submitted That Met QC Criteria

May 30, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Otitis Media With Effusion

Clinical Trials on Adenoidectomy

3
Subscribe